October 2025
How Your 2025 Agenda Addresses the Big Industry Challenges
#AntibodyUS #innovation #antibody
Tackling Antibody and Protein Engineering's Most Pressing Issues:
At Antibody Engineering & Therapeutics, our agenda has been carefully designed to tackle key challenges head-on - offering insights, case studies, and hands-on sessions that move the science forward. Take a look at some of the top challenges in the industry for 2025:
🔬 1. Overcoming Developability and Liabilities
The challenge: Many promising antibodies fail late due to aggregation, solubility, or manufacturability issues.
Our agenda response:
Pre-Conference Workshop: Engineering Considerations for Candidate Selection and Developability — practical guidance on integrating biophysical assessments and machine learning tools early in discovery.
Session Highlight: Predicting Antibody Developability Using Interpretable Machine Learning – explore AI-driven prediction models that flag risk before scale-up.
Track: Enhanced Efficacy Through Fc Engineering (Day 1) — discover how Fc modifications and glycoengineering improve stability, PK, and effector function.
Session Highlight: Integrating Metabolic Glycoengineering with Fc Engineering for Efficient Site-Specific Antibody Conjugates — solving the problem of heterogeneity in conjugation.
Our Day 1 sessions create a 360° view of developability — from computational insights to molecular optimization and manufacturing readiness.
🧩 2. Targeting Complex Biology with Novel Modalities
The challenge: Traditional IgGs often struggle to address “undruggable” targets or complex pathways. The next frontier involves multispecific antibodies, extracellular degraders, and new scaffolds — but these bring fresh design and safety hurdles.
Our agenda response:
Keynote: How Multispecific Biologics Are Transforming Pharmacotherapy — a forward-looking view on how format innovation is reshaping treatment paradigms.
Track: Novel Extracellular Protein Degraders & Beyond (Day 1) — includes talks such as:
Track: Novel Bispecific and Multispecific Antibodies (Day 2) — showcasing design strategies, high-throughput screening, and proximity-based therapeutics.
Track: Engineering Innovative Formats & Scaffolds (Day 2) — diving into nanobodies, knottins, and other next-gen formats.
Our program moves from visionary concepts (Day 1) to practical engineering strategies (Day 2) — equipping attendees to push format innovation without compromising safety or manufacturability.
🧠 3. Reducing Immunogenicity and Improving Safety
The challenge: Even the best-engineered antibodies can provoke immune responses, reducing efficacy or triggering safety concerns.
Our agenda response:
Pre-Conference Workshop: Mitigation of Biopharmaceuticals Immunogenicity During Drug Design — early-stage strategies for in silico and in vitro deimmunization.
Session: ADAx — A Novel Platform for Overcoming Immunogenicity in Biologics (Day 2) — cutting-edge approaches to dampen anti-drug antibody formation.
Track: Engineering Innovative Formats & Scaffolds — humanization and VH-only formats to minimize immunogenicity risks.
These sessions emphasize that safety isn’t an afterthought — it’s a design principle built into the molecule from day one.
💡 4. From Lab Bench to Market: Strategy, IP & Commercialization
The challenge: Scientific success is only half the story. The pathway to market — IP, funding, partnerships, and regulatory navigation — determines whether innovations reach patients.
Our agenda response:
Workshop: Innovate, Invest, Succeed: The Business Landscape of Antibody Therapeutics (Day 0) — covering funding strategies, partnerships, and the evolving biotech investment climate.
Session Highlights:
With these business-focused sessions, we help innovators translate science into sustainable impact.